Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 496-505

  Delord, Jean Pierre ^a   Tabernero, Josep ^b   García Carbonero, Rocío ^c   Cervantes, Andres ^d   Gomez Roca, Carlos ^e,f   Bergé, Yann ^a   Capdevila, Jaume ^b   Paz Ares, Luis ^c   Roda, Desamparados ^d   Delmar, Paul ^g   Oppenheim, David ^h   Brossard, Sophia Soehrman ^g   Farzaneh, Farzin ^h   Manenti, Luigi ⁱ   Passioukov, Alexandre ⁱ   Ott, Marion Gabriele ^g   Soria, Jean Charles ^e,f  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ Roche Glycart AG   (Switzerland)

Author keywords

Antibody dependent cell cytotoxicity; Colorectal neoplasms; Epidermal growth factor; GA201; Human; KRAS protein; Receptor; RG7160

Indexed keywords

BEVACIZUMAB; CD16 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CETUXIMAB; IMGATUZUMAB; IRINOTECAN; K RAS PROTEIN; PANITUMUMAB;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONJUNCTIVITIS; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRY SKIN; DYSGEUSIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAIL DISEASE; NATURAL KILLER CELL; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REGULATORY T LYMPHOCYTE; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VERY ELDERLY; XEROSIS;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; GA201; HUMAN; KRAS PROTEIN; RECEPTOR; RG7160;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84893639139     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.015     Document Type: Article

References (27)

1. E. Van Cutsem, C.H. Kohne, and E. Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
2. C. Bokemeyer, I. Bondarenko, and A. Makhson et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
3. E. Van Cutsem, M. Peeters, and S. Siena et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 2007 1658 1664
4. R.G. Amado, M. Wolf, and M. Peeters et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 1626 1634
5. S. Kasper, F. Breitenbuecher, and H. Reis et al. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade Oncogene 32 23 2013 2873 2881
6. J. Neumann, E. Zeindl-Eberhart, T. Kirchner, and A. Jung Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer Pathol Res Pract 205 12 2009 858 862
7. L.X. Qiu, C. Mao, and J. Zhang et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies Eur J Cancer 46 15 2010 2781 2787
8. A. Sartore-Bianchi, F. Di Nicolantonio, and M. Nichelatti et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS One 4 10 2009 e7287
9. C.A. Gerdes, V. Nicolini, and S. Herter et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab Clin Cancer Res 19 5 2013 1126 1138
10. L. Paz Ares, C. Gomez Roca, and J.P. Delord et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor (EGFR) in patients with advanced solid tumors J Clin Oncol 29 8 2011 3783 3790
11. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) Version 3.0. National Cancer Institute, 2010. Available at: http://ctep.cancer.gov [Last accessed 27 September 2010].
12. R. Pirker Pereira JR, von PJ, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 1 2011 33 42
13. A. Grothey, C.E. Van, and A. Sobrero et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 9863 2013 303 312
14. R. Gutzmer, J.C. Becker, and A. Enk et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician J Dtsch Dermatol Ges 9 3 2010 195 203
15. R.G. Pomerantz, E.D. Mirvish, and L.J. Geskin Cutaneous reactions to epidermal growth factor receptor inhibitors J Drugs Dermatol 9 10 2010 1229 1234
16. S. Tejpar, H. Piessevaux, and K. Claes et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study Lancet Oncol 8 5 2007 387 394
17. D.J. Freeman, T. Juan, and M. Reiner et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 3 2008 184 190
18. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
19. W. De Roock, D.J. Jonker, and F. Di Nicolantonio et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 16 2010 1812 1820
20. F. Cappuzzo, G. Finocchiaro, and E. Rossi et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 4 2008 717 723
21. M. Moroni, S. Veronese, and S. Benvenuti et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 5 2005 279 286
22. C. Campanella, M. Mottolese, and A. Cianciulli et al. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab J Transl Med 8 2010 36
23. M. Scartozzi, A. Mandolesi, and R. Giampieri et al. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab Oncologist 16 1 2011 53 60
24. F. Penault-Llorca, A. Cayre, and L. Arnould et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep 16 6 2006 1173 1179
25. K. Derecskei, J. Moldvay, K. Bogos, and J. Timar Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues Pathol Oncol Res 12 4 2006 243 246
26. K.Y. Chung, J. Shia, and N.E. Kemeny et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 9 2005 1803 1810
27. M. Hebbar, A. Wacrenier, and C. Desauw et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer Anticancer Drugs 17 7 2006 855 857